Resources
39 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 11/24/2021 (updated 3/26/2024)
This webinar will provide participants with an understanding of the role of the medical examiners and coroners in the surveillance of drug overdose deaths, as well as the current efforts to strengthen the death investigation system. The webinar will also cover an overview of the overdose fatality review process and tools available for implementation.
Posted 7/28/2023 (updated 3/26/2024)
The toolkit Stimulant Safety: Getting Amped Up to Reduce Harms When Using Stimulants was developed through the CDC-funded National Harm Reduction Technical Assistance Center in collaboration with the NASTAD Drug User Health team and consultants. This resource provides education on the reasons people take stimulants, how to minimize harm, reduce stigma around stimulants, support peoples' positive experiences, the intersection of stimulant use and sexual safety, and much more.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 9/4/2023 (updated 3/26/2024)
Two reports are now available from Fors Marsh, a research and communications firm who's reports work to highlight system problems like SUD. The "Road Map for Advancing a Recovery-Ready Nation" report examines recovery research and covers issues such as support services, housing, employment, workforce, stigma, etc. The "2022 Workplace Recovery Survey Report" covers background and understanding recovery in the workplace, policies, culture, experiences, and much more.
Posted 6/10/2022 (updated 3/27/2024)
During this session, we discussed what meaningful inclusion is (and is not) and we offered tangible steps toward developing trust, dignity, and inclusion of PWUDs. Meeting people where they are requires an element of internal self-reflection and honesty, both personally and within the organization.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 6/3/2022 (updated 3/27/2024)
This presentation highlighted The Health Wagon’s Rural Communities Opioid Response program, Strengthening and Expanding Substance Use Disorder and Opioid Use Disorder Prevention, Treatment and Recovery Programs in Southwest Virginia. The program is a consortium-based implementation that aims to reduce the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in rural communities in Southwest Virginia at the highest risk for SUD.
Posted 11/1/2022 (updated 3/27/2024)
Posted 12/13/2022 (updated 3/27/2024)